Abstract. A prospective study on dengue (DEN) viruses was initiated in October 1995 in Gondokusuman kecamatan, Yogyakarta, Indonesia. This report presents data from the first year of the study. The studied cohort included all children 4-9 years of age living in the kecamatan. Blood samples for serology were collected from 1,837 children in October 1995 and again in October 1996. Blood samples for virus isolation and serology were collected from cohort children who were seen in municipal health clinics with febrile syndromes or admitted to hospitals with a provisional diagnosis of dengue hemorrhagic fever. Dengue serotype antibody prevalence and 1995-1996 infection rates were calculated using a single dilution (1:60) 70% plaque reduction endpoint neutralization test. Prevalence of dengue antibody at the beginning of the study was DEN 1 ϭ 12%, DEN 2 ϭ 16%, DEN 3 ϭ 2%, DEN 4 ϭ 4%, and two or more dengue infections ϭ 22%. Total dengue antibody prevalence increased from 38% in 4-year-old children to 69% in 9-year-old children. During the observation period, primary dengue infection rates were DEN 1 ϭ 4.8%, DEN 2 ϭ 7.7%, DEN 3 ϭ 4.2%, and DEN 4 ϭ 3.4%, while two or more dengue infections occurred in 6.7% of the study population. The secondary dengue infection rate was 19.0%. From febrile cases, all four dengue viruses were isolated with DEN 3 predominating. Seven children were hospitalized, including one fatal case with a hospital diagnosis of dengue shock syndrome. Based upon presence of antibody in the initial cohort bleeding and the serologic response both weeks and several months following illness, all had secondary dengue infections. Neutralizing antibody patterns in the initial cohort bleeding and in late convalescent serum samples permitted recognition of dengue infection sequence in five patients: DEN 2-DEN 1 (3), DEN 2-DEN 4 (1), DEN 1-DEN 3 (1), and none in the sequence DEN 1-DEN 2. In the total cohort 6.5% of the observed secondary infections were of the sequence DEN 2-DEN 1, while 4.9% were DEN 1-DEN 2, a highly pathogenic sequence in previous studies. Reduced pathogenic expression of secondary DEN 2 with enhanced pathogenic expression of secondary DEN 1 infections was an unexpected finding. Further studies will be required to understand the respective contributions to pathogenicity of antibody from initial dengue infections versus the biological attributes of the second infecting dengue viruses.
The dengue (DEN) viruses (serotypes 1, 2, 3, and 4) are transmitted in nearly all tropical countries with a total population at risk in excess of 2.5 billion people. 1 It has been estimated that yearly dengue infections of humans are on the order of 50-100 million persons. 1 While initial dengue infections are moderately severe in adults and milder in children, sequential infections can, in some instances, result in severe and sometimes fatal dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). 2 This syndrome is increasingly a leading cause of hospitalizations and deaths among adults and children in both the Asian and American tropics. 3, 4 With four dengue virus serotypes in circulation, there are 12 possible sequences in which second dengue serotype infections may occur. In three previous prospective studies in Thailand and Myanmar, it was concluded that DHF/DSS occurred predominantly during secondary infections with DEN 2 viruses. [5] [6] [7] It is not known why DEN 2 plays such a role, but antibody residual from a first dengue infection or the antigenic composition or the genotype of the second infecting virus may determine the outcome during a secondary dengue infection. Enhancing antibody was incriminated as the crucial risk factor in a study in which pre-infection sera were examined for the presence or absence of cross-reactive antibodies that neutralized or enhanced a Bangkok DEN-2 strain in cultures of human mononuclear phagocytes. 8 More recently, it has been shown that at least two genotypes of DEN 2 virus are circulating in the American tropics and that secondary infections with an American genotype have not been associated with DHF/DSS. 9, 10 More information is required to identify the mechanisms of enhanced dengue disease. Study of complex causal mechanisms operating over two successive infections can only be approached through a prospective seroepidemiologic and clinical study format. After a thorough search of possible sites for such a prospective study, it was decided to investigate dengue virus infections in the city of Yogyakarta, Indonesia. This paper describes the site, the studied population, clinical, epidemiologic and virologic methods, and results obtained during the first year of the study.
MATERIALS AND METHODS
Study area: Yogyakarta. Yogyakarta, a city of 421,000, is the capital of Yogyakarta Province, located in southcentral Java. It is the site of one of Indonesia's oldest and most prestigious universities, Gadjah Mada University, which has an excellent Faculty of Medicine with long experience with diagnosis and management of DHF. The Province is divided into administrative districts called kabupatans. Each district is divided into 7 subdistricts called kecamatans and these, in turn, are divided into kelurahans and further, into ruken tetangga (RT) that are composed of approximately 50 families. Yogyakarta is a particularly opportune site to study dengue infections. As reported by the Directorate of Communicable Disease Control, Ministry of Health, Jakarta, the city of Yogyakarta has consistently had one of the highest DHF hospitalization rates in Indonesia for the past two decades (Director, Epidemiology Unit, Ministry of Health, Jakarta, In-FIGURE 1. Principal features of kecamatan Gondokusuman, the prospective dengue study site in Yogyakarta, Indonesia (inset). donesia, unpublished data). Based on data furnished by the Yogyakarta Health Department, during the five-year period 1990-1994, 2,772 dengue cases were hospitalized in the province of Yogyakarta, and 2,082 of these were children less than 15 years of age. Data from the city of Yogyakarta showed that the kecamatan of Gondokusuman (Figure 1 ) consistently reported the highest number of children hospitalized with an annual mean of 164 cases over a 4-year period. The hospitalization rate in 6-, 7-, and 8-year-old children was approximately 4/1,000. Data showed that cases were hospitalized throughout the year with seasonal lows occurring in July-September, which are the dry months of the year. Ninety-six percent of DHF cases hospitalized in Yogyakarta Province attended four city hospitals, the Gahja Mada University Hospital (Dr. Sardjito), which is governmental, and three private hospitals, Bethesda, Panti Rapih, and Muhammidiah. Nearly all cases attended the first three of these hospitals.
From the data cited, kecamatan Gondokusuman was se- lected as the study site. This kecamatan has a stable population that represents a wide range of socioeconomic strata. The majority of the residents are Javanese. In addition, all three participating study hospitals were either within the boundaries of the kecamatan (Bethesda, Panti Rapih) or approximately 0.75 km away (Dr. Sardjito) (Figure 1 ). An additional hospital, the Army Hospital Dantara, was later included as a study participant. Study design. A cohort of children was recruited and bled at the beginning of the study and one year later. Any child in the cohort that developed a fever was requested to go to one of the outpatient clinics participating in the study. This included outpatient clinics associated with the hospitals and two government outpatient clinics (PUSKESMAS), Gondokusuman I and II. These were located within the administrative boundaries of Gondokusuman. Six months after beginning the study, a questionnaire administered to 10% of participating families indicated significant use of the outpatient clinic of the Army Hospital, Dantara (located within Gondokusuman) and the PUSKESMAS, Danurejan I. These were added to the study. Febrile children were studied for recent dengue infection. Children suspected of having DHF were admitted to one of the participating hospitals where they were studied virologically and serologically. The cost of the clinic visits or hospitalizations was subsidized by the study.
Population cohort. The study cohort was recruited from the entire population of Gondokusuman with the assistance of the head of the kecamatan (Camat) and his staff. The Camat sent a letter to all parents describing the study. Families were then verbally briefed by the local coinvestigators in public meetings usually at the level of RTs. During these meetings, the study was described in more detail and questions were answered. About one week before the study began, another letter was sent to families with eligible children explaining when and where the children could enroll in the study. All children were enrolled on the day they were bled. Each family or representative was required to sign a consent form for each child. The consent forms were translated into Bahasa Indonesia and approved by both the Human Use Committees of NAMRU-2 and Gadja Mada University and the Ministries of Health and Social Welfare. This consent form provided a description of the proposed study, detailing risks associated with venipuncture, the name and addresses of investigators in Yogyakarta and NAMRU-2 and the name of the chair of the NAMRU-2 Human Use Committee where questions could be directed concerning scientific or ethical issues. The form was in triplicate: one copy was given to the parent, one to the local principle investigator, and one was archived at NAMRU-2. Prior to signing the consent form, the study and contents of the consent form were verbally explained again by NAMRU-2 or Gadjah Mada personnel. The child's name, date of birth, sex, name of parent or guardian and house address were obtained. Each family was administered a short questionnaire eliciting the general health of the family, previous episodes of dengue fever or DHF in family members and general knowledge of dengue fever. Each child was assigned a unique study number and photographed. An identification card was issued to participants for use by health care providers. On the back of the card were instructions in Bahasa Indonesia stating the health benefits and the locations of the participating outpatient clinics and hospitals. A designated person at each participating clinical facility was given a list of the names of the entire cohort to facilitate identification of study children. The study number was used for all laboratory and data analyses to ensure patient confidentiality.
Cohort serum collection. Between October 23 and November 2, 1995, initial blood samples (S1) from the cohort children were collected into 5-ml heparin-containing Vacutainer tubes. Plasma was separated from red blood cells by centrifuging the tubes at 1,600 ϫ g for 15 min. Plasma was decanted into two screw-capped cryovials (1.25 ml per tube) and stored at Ϫ20ЊC. In a similar fashion, a second blood sample (S2) was collected from the cohort children between September 23 and October 11, 1996. Altogether, 2,149 children were enrolled in the study, 1,992 of whom presented for the collection of a second blood sample (Table 1) .
Plasma for virus isolation and serology. Acute phase venous blood samples were collected in 5-ml citrated Vacutainer tubes (Becton Dickinson, Rutherford, NJ) from children who visited clinical facilities. These were placed into a 4ЊC refrigerator immediately after collection. The samples were collected and delivered to the Dr. Sardjito Hospital by a courier using a cold chest, usually within 1-2 hr of sample collection. In the laboratory, the blood tubes were centrifuged at 1,600 rpm for 10 min to separate red blood cells and plasma. A sterile, graduated, disposable transfer pipette was used to collect plasma, which was dispensed into 2 sterile cryovials (1 ml per vial). With the same transfer pipette, the buffy coat and approximately 0.5 ml of plasma above the buffy coat was collected and dispensed into 2 sterile cryovials. All samples were placed in liquid nitrogen. A convalescent phase plasma sample was collected in a 3-ml Vacutainer tube and processed as described above. The liquid nitrogen tank was transferred to NAMRU-2 at least once each month.
Recognition and diagnosis of dengue and DHF/DSS. Blood samples were collected from any cohort participant if they had a fever of 38ЊC with symptoms suggesting dengue infection. When children suspected of DHF/DSS were admitted to study hospitals, residence and participation of the child in the study were determined promptly and clinical coordinators were notified. In the hospital, signs and symptoms were charted daily on a clinical flow sheet to facilitate recognition of DHF/DSS in accordance with World Health Organization (WHO) diagnostic criteria. 11 Microhematocrit determinations were made on the pediatric ward by nursing personnel. Platelet counts were made by quantitative methods using either a Coulter (Hialeah, FL) counter or manual methods in the hospital laboratory.
Case definition. Charts from each of the suspected DHF cases were reviewed by a pediatric infectious disease specialist who was not associated with the study and without knowledge of the serologic results. Case definitions of DHF/ DSS used were those established by the WHO. 11 To fulfill criteria for DHF/DSS, patients had two or more hematocrit determinations that were 20% higher than the convalescent phase value and two or more platelet counts that were at or below 100,000/mm 3 . As a supplement or alternative to defined hemoconcentration, a pleural effusion detected upon an upright chest radiograph was taken as evidence of increased vascular permeability. Cases of dengue etiology not meeting the criteria for DHF/DSS were classified as cases of dengue fever.
Virus isolation. Acute phase plasma and buffy coat samples were processed for virus isolation in C6/36, Vero, and baby hamster kidney (BHK)-21 (clone 13) tissue culture cells and by intrathoracic inoculation of Toxorhynchites splendens. Each of the cell lines was grown to confluency in 24-well plates (Costar, Cambridge, MA). For plasma and buffy coat virus isolation, each sample was diluted 1:10 in borate saline supplemented with 8% bovine albumin (pH 7.9) (BABS) and dispensed in a volume of 0.3 ml/well into duplicate wells of each of the three cells lines. Three to five days later, the inoculated cells were blind passed into 15-ml plastic tubes containing the appropriate cell line. Seven days later, cells were removed from the tubes, centrifuged, applied to a glass slide, air-dried, and examined for specific fluorescence with a broadly reactive flavivirus monoclonal antibody (4G2). 12 Specific serotypes were identified using monoclonal antibodies kindly provided by the Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention (Fort Collins, CO). In the case of T. splendens, each mosquito was inoculated with 0.85 l of undiluted plasma. After 14 days, the mosquito was ground in BABS and inoculated into C6/36 cells. The C6/36 cells were then processed as described above for blind passaging.
Polymerase chain reaction (PCR) methods. The PCRbased examination of acute phase plasma and buffy coat samples was carried out as previously described. 13 Briefly, viral RNA was extracted from plasma and buffy coat samples and reverse transcribed (RT-PCR). The resulting cDNA was subjected to a primer pair corresponding to conserved sequences present in all of the dengue serotypes. The resultant PCR product was subsequently subjected to a standard nested PCR using serotype specific oligonucleotides. The reaction products were then electrophoresed in a 2% agarose gel and the amplicon sizes were compared to virus standards. Negative and positive virus controls were included in each RT-PCR and PCR run.
Plaque reduction neutralization tests (PRNTs). Single dilution method. The method described by Sangkawibha and others 5 was followed. Briefly, sera or plasma to be tested were diluted to 1:30 in phosphate-buffered saline and 0.2 ml of the diluted serum was added to an equal amount of a suspension of dengue viruses (final serum dilution of 1:60) containing 15-25 plaque-forming units per 25 l. The mixture of sera and virus was incubated for 60 min at 37ЊC. Virus-serum mixtures were then inoculated (50 l) in triplicate on BHK-21 (clone 13) cell suspensions in 24-well polystyrene tissue culture plates (Costar). The plates were covered with carboxymethyl cellulose and incubated at 37ЊC for 6 days, the fluid was removed, and the cells were washed in distilled water and stained with naphthol blue-black solution by the method of Morens and others. 14 Serum dilution method. Plaque reduction neutralizing antibody titers were obtained by incubating viruses with serial two-fold dilutions of plasma or sera starting at 1:10. End point titers were then determined by the highest dilution that gave a greater than or equal 70% reduction in plaque numbers.
Interpretation of results. The single dilution PRNT was used to determine the baseline prevalence and one-year incidence of DEN virus infections in the study cohort. Following previously published criteria, 5,15 children whose S1 sam- ple when diluted to 1:60 neutralized only a single DEN virus serotype (Ն 70% plaque reduction) were considered to have been infected only with that DEN virus. Children whose sera neutralized more than one DEN serotype were considered to have been infected with two or more DEN viruses. For determining incidence, a primary infection was assumed when the S1 sample from a child showed no dengue neutralizing antibodies and the S2 sample neutralized a single dengue virus. A secondary dengue infection was assumed when the S1 sample neutralized a single dengue virus and the S2 sample neutralized two viruses. Children whose initial sample neutralized a single DEN virus that seroconverted to two or more DEN viruses, and children whose S1 sample neutralized two or more DEN viruses that seroconverted to another DEN virus were classified as tertiary infections. Neutralizing antibody end point antibody titers were determined in the serum dilution PRNT for all cohort children seen at the local health clinics or admitted to the study hospitals with clinically suspected DEN infections. A four-fold or greater increase in neutralizing antibody titer between the S1 sample and the acute phase serum or between the acute phase serum and any convalescent phase serum was considered diagnostic for DEN virus infection.
RESULTS
Estimated dengue antibody prevalence prior to the 1995-1996 transmission season. Altogether, 1,837 plasma samples obtained from children who were bled in October 1995 and again one year later were tested for dengue neutralizing antibodies. In the initial bleeding, the prevalence of dengue neutralizing antibodies by age and serotype specificity is shown in Figure 2 and Table 2 . Based on the single dilution (1:60) PRNTs, in the first bleeding of the cohort, 43.8% of 4-9-year-old children were seronegative, 12.0% were immune to DEN 1, 16.3% to DEN 2, 2.2% to DEN 3, 3.8% to DEN 4, and 21.8% were immune to two or more dengue types (Table 2 ). In each age group, antibodies to DEN 2 and 1 predominated. The fraction of sera containing antibodies to two or more dengue types increased progressively with age as did total dengue antibodies, which increased from 37.2% prevalence in 4-year-old children to 69.7% in 9-year-old children.
Incidence of dengue virus infections. The overall incidence for one or more DEN virus infections in the cohort over the one-year study period was 29.2% (536 of 1,837). Among the children without antibody in their S1 sample, 26.8% (216 of 805) seroconvered (Table 3) . Primary infections were recorded in 20.1% of these children with 4.8% seroconverting to DEN 1, 7.7% to DEN 2, 4.2% to DEN 3, and 3.4% to DEN 4, while 6.7% seroconverted to two or more DEN viruses. Among the children with DEN neutralizing antibody in their S1 sample, 31.0% (320 of 1,032) seroconverted to one or more additional DEN serotypes. Secondary dengue infections were seen in 19.0% (120 of 631) of the children whose S1 samples contained neutralizing antibodies to only one DEN virus (Table 4) . Based on results in the single dilution PRNT, infections in the sequence DEN 2 followed by DEN 1 were observed most frequently followed by infections in the sequence DEN 1-DEN 2. Tertiary infections were seen in 15.4% (97 of 631) of these children. Of the children whose S1 sample contained neutralizing antibody to Ն 2 DEN viruses there were 25.7% (103 of 401) who seroconverted to another DEN serotype. Diagnosis of dengue fever and DHF/DSS cases. Within the cohort of 1,837 children, a total of 107 study children were seen in hospital outpatient departments or government clinics of which 96 were diagnosed as fevers of unknown origin. Eleven of the febrile patients had serologic or virologic evidence of a recent dengue infection and were classified as DEN fever cases (Table 5) . Four cases were primary dengue infections, and 7 were secondary infections. Seven dengue viruses of all four serotypes were identified from these cases: DEN 1 (1), DEN 2 (1), DEN 3 (4), and DEN 4 (1) .
Six hospitalized children with confirmed DEN virus infections met the case definition of DHF (Table 6 ). Three of these children were diagnosed as DSS cases. Another child died of a DSS-like illness in a non-study hospital. This child's pre-illness serum had monotypic neutralizing antibodies to DEN 1. Five of the six patients hospitalized with confirmed DHF/DSS experienced secondary dengue infections and one had a tertiary infection. The DEN virus infection sequences in the five secondary infections were classified based on the neutralizing antibody patterns in the S1 and the convalescent sera as DEN 2-DEN 1 (3), DEN 2-DEN 4 (1) and DEN 1-DEN 3 (1) . Dengue 3 virus also was identified by PCR from the acute phase serum of the last case.
DISCUSSION
In the first year of the Yogyakarta prospective study, the total dengue virus infection rate was 29.2%. All four dengue viruses were transmitted, with DEN 2 infections slightly predominating based on seroconversion data (Table 3) . These infections occurred in a partially immune population. For example, among 4-9-year-old children, an average of 56.2 % had PRNT antibodies against one or more types, with a range of 37.2-69.7%. Of these, 34.3% were immune to a single dengue virus and at risk for a second dengue infection. During the study period, 120 of these children seroconverted to a second dengue virus. Among the study participants, six children hospitalized with a diagnosis of DHF (3) or DSS (3) had confirmed dengue virus infections. Five of these patients had secondary infections while the remaining patient appeared to have a tertiary infection. The five secondary infections represent 4.2% of the total secondary infections. A seventh child hospitalized for DHF died in a non-study hospital with a DSS-like illness, but we were not able to confirm the diagnosis. Therefore, 3 or 4 study subjects had DSS, or 2.5-3.3% of secondary dengue infections. Each of these children had monotypic dengue neutralizing antibodies in their pre-transmission season (S1) serum samples and TABLE 6 Clinical and laboratory findings on 6 children from the prospective study who were hospitalized with dengue hemorrhagic fever (DHF), 1995-1996, in Gondokusuman, Yogyakarta, Indonesia ϭ serosurvey 1 (pre-illness); S2 ϭ serosurvey 2 (late convalescent).
documented secondary dengue infections (Table 6 ). The percentage of hospitalized patients with secondary dengue infections is at the high end of the 0.5-3.6% range measured in previous studies. [5] [6] [7] [16] [17] [18] The lower of these calculations (0.5%) were made in Thailand and Myanmar and counted only DSS cases. It is possible that discrepancies in comparative rates of DHF/DSS among secondary dengue infections could be due to more stringent diagnostic criteria applied in Thailand and Myanmar than in Indonesia. Prior to 1980, prospective studies of dengue calculated dengue infection rates using hemagglutination-inhibition (HI) tests. [16] [17] [18] This leads to two problems: 1) with the passage of time, an unknown fraction of HI antibodies degrade below test detection threshold and 2) these tests are unable to distinguish monotypic from multitypic immune individuals. Therefore, HI antibodies overestimate primary infections and underestimate secondary infections, and each impacts on estimates of the ratio of hospitalized cases to secondary dengue infections.
To increase the specificity of the neutralizing antibody results in our study, we used the single dilution PRNT, requiring 70% plaque reduction at a 1:60 serum dilution, to determine DEN prevalence and incidence. Like the HI test, the single dilution PRNT may have underestimated the prevalence of primary DEN infections in the S1 serosurvey resulting in an underestimate of the incidence of secondary infections that would increase the ratio of DHF/DSS cases to secondary infections. As in all other prospective studies, all hospitalized dengue cases experienced secondary dengue infections. [5] [6] [7] [16] [17] [18] It was surprising to discover in the cohort population that 31 children experienced infections in the sequence DEN 1 followed by DEN 2, but these yielded no hospitalizations. If the ratio observed in Rayong, Thailand is applied to Yogyakarta, six DSS cases (or approximately 15 DHF/DSS cases) would have been expected to occur with the number of observed secondary dengue infections in the sequence DEN 2 followed by DEN 1. 5 Instead, 41 infections, in the sequence DEN 2 followed by DEN 1, resulted in three DHF (two DSS) patients (7.3%). These data are the reverse of the results from the Rayong, Thailand study of 1980 (5) in which 20% of DEN 1-DEN 2 infections resulted in DSS. Secondary DEN 2 infections were the predominant cause of DHF in the Cuban outbreak of 1981, 15 the 1980 Bangkok study, 6 and in a prospective study in Yangon, Myanmar in 1984-1988. 7 Observations made in Thailand in the early 1980s cast doubts on the pathogenic potential of secondary DEN 1 infections. 5, 6 In contrast, DEN 1 viruses have been isolated from children hospitalized with secondary infection DHF/DSS cases in several intermittent 3-or 4-year periods during 1973-1995 at the Bangkok Children's Hospital (Nisalak A, Vaughn D, unpublished data). During the entire 36 years of observations on dengue infections at Bangkok Children's Hospital, secondary DEN 2 never disappeared as a dominant cause of secondary DHF/DSS 19 (Nisalak A, Vaughn D, unpublished data). Thus, the observed disappearance of secondary DEN 2 DHF/DSS in Yogyakarta in the face of active transmission of strains of this virus, while admittedly from a small sample, is unique.
What might result in such a phenomenon? Data available to date yield two explanatory models: 1) dengue antibody from the first infection may either modulate or enhance sec-ondary infections and 2) dengue viruses differ in their inherent ability to cause DHF during a second infection. In model 1, initial dengue infection might result either in low concentrations of cross-reactive neutralizing antibodies or in dengue infection-enhancing antibodies. The former would be expected to down-regulate secondary infections to clinically mild illnesses and the latter to up-regulate infection to DHF as described by Kliks and others. 8 For model 2, it has been proposed that among the DEN 2 viruses five genotypes exist. Two Southeast Asian genotypes produce secondary infection DHF while the American genotype does not. 9 This phenomenon has been observed directly in a prospective study of dengue infections in Peru where among an estimated 31,000 secondary DEN 2 infections with the American genotype in the sequence DEN 1-DEN 2, no DHF/ DSS cases were observed. 10 We have no ready answer as to why DEN 2 viruses have been consistently pathogenic during secondary dengue infections in Thailand, but seem to have lost their pathogenicity in Indonesia. According to model 1, a possibility is that DEN 1, 3, and 4 viruses circulating in Yogyakarta are antigenically unique and carry epitopes that raise cross-reacting neutralizing antibody to Indonesian DEN 2 strains. Correspondingly, some Indonesian DEN 2, 3, and 4 viruses might fail to carry epitopes that neutralize DEN 1 viruses, thus generating enhancing antibodies for DEN 1. We intend to explore both models by genotyping Indonesian dengue viruses isolated in 1995 to determine whether genetic differences exist compared with strains of the same serotype that circulated in Indonesia earlier or in other parts of Southeast Asia. Furthermore, we plan to extend the observations of Kliks and others 8 to determine if antibody obtained prior to the onset of DHF due to secondary DEN 1 infection neutralizes or enhances growth of Yogyakarta DEN 1 viruses when incubated in human mononuclear cell cultures. Fortunately, it has been possible to secure funding to extend the prospective study beyond one year. Due to normal rotation of the principal investigator, laboratory testing of these new cohort samples has not been completed. New cases enrolled during the sizable DHF/DSS epidemics of 1996-1997 and 1997-1998 are expected to expand the sequential infection data sets. It is hoped that additional data and new research approaches will yield clues to the mechanism(s) that control the pathogenesis of severe dengue disease.
